1. Resolution of NASH and hepatic fibrosis by the GLP-1R/GcgR dual-agonist Cotadutide via modulating mitochondrial function and lipogenesis
- Author
-
Christopher J. Rhodes, James Conway, Jacqueline Naylor, James L. Trevaskis, Martin R. Larsen, Michael Feigh, Stephanie Oldham, Karly M. Mather, Rhianna C. Laker, Arkadiusz Nawrocki, Owen P. McGuinness, Michelle L. Boland, Louise Lantier, Hilary J. Lewis, Cristina M. Rondinone, Sanne Skovgård Veidal, Joseph Grimsby, Brandon B. Boland, Silvia Guionaud, and Lutz Jermutus
- Subjects
Blood Glucose ,Liver Cirrhosis ,Male ,Proteomics ,medicine.medical_specialty ,Endocrinology, Diabetes and Metabolism ,Glucagon-Like Peptide-1 Receptor ,Article ,chemistry.chemical_compound ,Mice ,Non-alcoholic Fatty Liver Disease ,Physiology (medical) ,Internal medicine ,Internal Medicine ,medicine ,Animals ,Mice, Knockout ,business.industry ,Liraglutide ,Lipogenesis ,Fatty liver ,Body Weight ,Obeticholic acid ,Cell Biology ,medicine.disease ,Mitochondria ,Endocrinology ,chemistry ,Diabetes Mellitus, Type 2 ,Liver ,Liver function ,Steatohepatitis ,Steatosis ,Hepatic fibrosis ,business ,Peptides ,Glycogen ,medicine.drug - Abstract
Non-alcoholic fatty liver disease and steatohepatitis are highly associated with obesity and type 2 diabetes mellitus. Cotadutide, a glucagon-like protein-1 receptor (GLP-1R) and glucagon receptor (GCGR) agonist, was shown to reduce blood glycaemia, body weight and hepatic steatosis in people with type 2 diabetes mellitus. Here, we demonstrate that the effects of cotadutide in reducing body weight and food intake and improving glucose control are predominantly mediated through Glp-1 signalling, whereas its action on the liver to reduce lipid content, drive glycogen flux and improve mitochondrial turnover and function are directly mediated through Gcg signalling. This was confirmed by the identification of phosphorylation sites on key lipogenic and glucose metabolism enzymes in liver of mice treated with cotadutide. Complementary metabolomic and transcriptomic analyses implicated lipogenic, fibrotic and inflammatory pathways, consistent with a unique therapeutic contribution of GCGR agonism by cotadutide in vivo. Notably, cotadutide also alleviated fibrosis to a greater extent than liraglutide or obeticholic acid, despite dose adjustment to achieve similar weight loss in two preclinical mouse models of NASH. Thus, cotadutide, via direct hepatic (GcgR) and extrahepatic (Glp-1R) effects, exerts multifactorial improvement in liver function and is a promising therapeutic option for the treatment of steatohepatitis.
- Published
- 2020
- Full Text
- View/download PDF